Takeda Seeks To Buy Development, Marketing Rights For New Drugs (Japan)
This article was originally published in PharmAsia News
Executive Summary
Looking ahead to 2010, Takeda Pharmaceutical is counting the costs of developing a drug from scratch and looking to partner with other companies for compounds in at least five areas. President Yasuchika Hasegawa says many of its primary drugs face patent expirations, so the firm is looking to buy development and marketing rights for new drugs in areas where the firm's pipeline is lacking, in depression and schizophrenia and irritable bowel syndrome. One urgent quest of Takeda is to find outside sources for lipid-lowering agents since its own TAK-475 faces concerns about side affects. (Click here for more - may require subscription
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.